Market›Health Care›Health Care Technology›Health Care Technology
NETRAMARK HLDGS INC

AINMF

$0.62Sep 20, 2021 – Apr 24, 2026
Health CareHealth Care Technology$52M
MVM
+$0.0M

Every news event mapped to its market reaction — 25 events, 56 months of data. No predictions, just what happened.

PositiveNegativeNo data· Dot size = magnitude · Scroll to zoom · Drag to pan
Hover to inspect

Want the full written briefing?

The chart shows what moved — the briefing shows why. Sourced, dated, no hot takes.

Subscribe on Substack →

News Events

DateReturnCategorySourceHeadline
2022-07-19-12.1%executiveSeeking AlphaNurosene Health appoints Swapan Kakumanu as CFO
2024-01-30+11.7%expansionSeeking AlphaNetraMark signs third contract with a large biopharma company
2022-01-27+10.0%newsSeeking AlphaNurosene teams up for research on mitochondrial genetics in neurodegenerative diseases
2022-01-26+9.8%earningsSeeking AlphaNurosene Heath  GAAP EPS of -C$0.20
2026-03-25-6.7%analystMT NewswiresNetraMark Collaborating With Italian Company To Analyze Phase II Oncology Dataset
2026-03-25-6.7%newsGlobeNewswireNetraMark Announces Strategic Oncology Research Collaboration with Fondazione per la Medicina Personalizzata to Analyze Landmark ROME Trial Dataset
2026-03-25-6.7%newsStock TitanAI will sift 400-patient cancer trial data for responder subgroups - Stock Titan
2026-04-09-6.4%newsGlobeNewswireNetramark-Authored, Peer-Reviewed Article Suggests Psychedelics Might Not Only Affect Brain Chemistry, They May Also Involve Quantum-Level Processes Inside the Brain
2026-04-09-6.4%newsStock TitanNetraMark authors testable theory on why psychedelic responses differ - Stock Titan
2025-03-10+6.3%newsSeeking AlphaNetraMark raises $1.85 million from warrants exercise
2026-03-19+1.9%newsGlobeNewswireNetraMark Unveils AI-Discovered Treatment-Responsive Subgroups in A4 Alzheimer’s Trial at AD/PD Conference
2022-08-24-1.7%executiveSeeking AlphaNurosene Health appoints Douglas James Cook as Chief Medical Officer
2026-03-11+1.6%expansionGlobeNewswireNetraMark Signs Contract With Global Biopharmaceutical Company to Analyze Phase 2 Depression Trial Data
2026-04-20+0.9%expansionZacks Small Cap ResearchAINMF: Expanding Number of Agreements, Cash Runway Extended
2026-04-20+0.9%legalGlobeNewswireNetramark Comments on U.S. Executive Order to Accelerate Treatments for Serious Mental Illness and Highlights the Need for Regulatory‑Grade Trial Design in Psychedelic Development
2026-04-20+0.9%newsStock TitanAs U.S. backs mental illness drug research, NetraMark presses for tighter trials - Stock Titan
2026-04-22-0.6%newsGlobeNewswireNetraMark Positioned to Advance Psychedelic Clinical Trials Following U.S. Executive Order, Supported by Peer-Reviewed Research and Active Programs
2026-04-22-0.6%newsStock TitanPsychedelic trials face placebo noise; NetraMark points to AI data tools - Stock Titan
2023-11-06-0.5%executiveSeeking AlphaNetraMark appoints Larry Alphs as chief medical officer
2026-02-19-0.5%newsGlobeNewswireNetraMark Closes Final Tranche of $3.5 Million Private Placement
2026-01-13+0.3%newsSeeking AlphaNetraMark announces private placement financing
2026-01-13+0.3%newsStock TitanAI trial firm NetraMark seeks up to C$3.5M to grow NetraAI projects - Stock Titan
2026-02-13-0.2%newsMT NewswiresNetraMark Holdings Announces Uplisting to Toronto Stock Exchange
2026-02-13-0.2%newsThe Manila TimesNetramark Announces Uplisting to Toronto Stock Exchange - The Manila Times
2025-04-10-0.1%expansionStock TitanNetraMark's AI Revolution in Clinical Trials: Major Partnership Signals Growth Acceleration - Stock Titan
tickerdossier.comtickerdossier.substack.com